Determination of the hemoglobin F program in human progenitor-derived erythroid cells

Alan David Friedman, D. C. Linch, B. Miller, J. M. Lipton, J. Javid, D. G. Nathan

Research output: Contribution to journalArticle

Abstract

The absolute adult and fetal hemoglobin (HbF) contents of the erythroid cells derived from the differentiation of normal human and simian erythroid progenitors and of the peripheral blood erythroid burst-forming units (BFU-E) of patients with nondeletion hemoglobinopathies have been measured with a sensitive radioligand immunoassay. The HbF content varied between 0.13 and 2.96 pg/cell, representing between 0.7% and 19.6% of the total hemoglobin with a mean value of 7.0%. The absolute content of HbF was indistinguishable in the well-hemoglobinized progeny of marrow erythroid colony-forming units, marrow or blood BFU-E, or of mixed colony-forming units. The term HbF program refers to this inherent capacity to produce fetal hemoglobin (HbF) in the erythroid cells derived from these progenitors in vitro. The HbF content of marrow erythroblasts as determined by the same radioligand immunoassay was similar to that found in the peripheral blood, suggesting that the switch off of γ-chain production occurs after the erythroid colony-forming unit stage of maturation. Increasing concentrations of a crude erythropoietin-containing preparation induced higher numbers of erythroid colonies, which were larger in size, but the HbF program was unaffected. In contrast to the hemoglobin accumulation in human progenitor-derived colonies, simian progenitor-derived colonies produced considerably more HbF, and the amount of HbF was strongly influenced by progenitor maturity. Assays of the HbF content of erythroblasts derived from culture of the peripheral blood BFU-E of patients with nondeletion hemoglobinopathies and their parents showed that the HbF program in the progenitors of such patients is highly variable. Some produce only a slight excess of HbF in progenitor-derived erythroblasts, whereas others have extraordinarily high HbF programs. The molecular basis of this variability is presently unknown.

Original languageEnglish (US)
Pages (from-to)1359-1368
Number of pages10
JournalJournal of Clinical Investigation
Volume75
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Erythroid Precursor Cells
Erythroblasts
Hemoglobinopathies
Bone Marrow
Immunoassay
Hemoglobins
Erythroid Cells
Erythropoietin
Cell Differentiation
Stem Cells
Parents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Friedman, A. D., Linch, D. C., Miller, B., Lipton, J. M., Javid, J., & Nathan, D. G. (1985). Determination of the hemoglobin F program in human progenitor-derived erythroid cells. Journal of Clinical Investigation, 75(4), 1359-1368.

Determination of the hemoglobin F program in human progenitor-derived erythroid cells. / Friedman, Alan David; Linch, D. C.; Miller, B.; Lipton, J. M.; Javid, J.; Nathan, D. G.

In: Journal of Clinical Investigation, Vol. 75, No. 4, 1985, p. 1359-1368.

Research output: Contribution to journalArticle

Friedman, AD, Linch, DC, Miller, B, Lipton, JM, Javid, J & Nathan, DG 1985, 'Determination of the hemoglobin F program in human progenitor-derived erythroid cells', Journal of Clinical Investigation, vol. 75, no. 4, pp. 1359-1368.
Friedman, Alan David ; Linch, D. C. ; Miller, B. ; Lipton, J. M. ; Javid, J. ; Nathan, D. G. / Determination of the hemoglobin F program in human progenitor-derived erythroid cells. In: Journal of Clinical Investigation. 1985 ; Vol. 75, No. 4. pp. 1359-1368.
@article{41da87ff1c7b4492943aebfab308961c,
title = "Determination of the hemoglobin F program in human progenitor-derived erythroid cells",
abstract = "The absolute adult and fetal hemoglobin (HbF) contents of the erythroid cells derived from the differentiation of normal human and simian erythroid progenitors and of the peripheral blood erythroid burst-forming units (BFU-E) of patients with nondeletion hemoglobinopathies have been measured with a sensitive radioligand immunoassay. The HbF content varied between 0.13 and 2.96 pg/cell, representing between 0.7{\%} and 19.6{\%} of the total hemoglobin with a mean value of 7.0{\%}. The absolute content of HbF was indistinguishable in the well-hemoglobinized progeny of marrow erythroid colony-forming units, marrow or blood BFU-E, or of mixed colony-forming units. The term HbF program refers to this inherent capacity to produce fetal hemoglobin (HbF) in the erythroid cells derived from these progenitors in vitro. The HbF content of marrow erythroblasts as determined by the same radioligand immunoassay was similar to that found in the peripheral blood, suggesting that the switch off of γ-chain production occurs after the erythroid colony-forming unit stage of maturation. Increasing concentrations of a crude erythropoietin-containing preparation induced higher numbers of erythroid colonies, which were larger in size, but the HbF program was unaffected. In contrast to the hemoglobin accumulation in human progenitor-derived colonies, simian progenitor-derived colonies produced considerably more HbF, and the amount of HbF was strongly influenced by progenitor maturity. Assays of the HbF content of erythroblasts derived from culture of the peripheral blood BFU-E of patients with nondeletion hemoglobinopathies and their parents showed that the HbF program in the progenitors of such patients is highly variable. Some produce only a slight excess of HbF in progenitor-derived erythroblasts, whereas others have extraordinarily high HbF programs. The molecular basis of this variability is presently unknown.",
author = "Friedman, {Alan David} and Linch, {D. C.} and B. Miller and Lipton, {J. M.} and J. Javid and Nathan, {D. G.}",
year = "1985",
language = "English (US)",
volume = "75",
pages = "1359--1368",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Determination of the hemoglobin F program in human progenitor-derived erythroid cells

AU - Friedman, Alan David

AU - Linch, D. C.

AU - Miller, B.

AU - Lipton, J. M.

AU - Javid, J.

AU - Nathan, D. G.

PY - 1985

Y1 - 1985

N2 - The absolute adult and fetal hemoglobin (HbF) contents of the erythroid cells derived from the differentiation of normal human and simian erythroid progenitors and of the peripheral blood erythroid burst-forming units (BFU-E) of patients with nondeletion hemoglobinopathies have been measured with a sensitive radioligand immunoassay. The HbF content varied between 0.13 and 2.96 pg/cell, representing between 0.7% and 19.6% of the total hemoglobin with a mean value of 7.0%. The absolute content of HbF was indistinguishable in the well-hemoglobinized progeny of marrow erythroid colony-forming units, marrow or blood BFU-E, or of mixed colony-forming units. The term HbF program refers to this inherent capacity to produce fetal hemoglobin (HbF) in the erythroid cells derived from these progenitors in vitro. The HbF content of marrow erythroblasts as determined by the same radioligand immunoassay was similar to that found in the peripheral blood, suggesting that the switch off of γ-chain production occurs after the erythroid colony-forming unit stage of maturation. Increasing concentrations of a crude erythropoietin-containing preparation induced higher numbers of erythroid colonies, which were larger in size, but the HbF program was unaffected. In contrast to the hemoglobin accumulation in human progenitor-derived colonies, simian progenitor-derived colonies produced considerably more HbF, and the amount of HbF was strongly influenced by progenitor maturity. Assays of the HbF content of erythroblasts derived from culture of the peripheral blood BFU-E of patients with nondeletion hemoglobinopathies and their parents showed that the HbF program in the progenitors of such patients is highly variable. Some produce only a slight excess of HbF in progenitor-derived erythroblasts, whereas others have extraordinarily high HbF programs. The molecular basis of this variability is presently unknown.

AB - The absolute adult and fetal hemoglobin (HbF) contents of the erythroid cells derived from the differentiation of normal human and simian erythroid progenitors and of the peripheral blood erythroid burst-forming units (BFU-E) of patients with nondeletion hemoglobinopathies have been measured with a sensitive radioligand immunoassay. The HbF content varied between 0.13 and 2.96 pg/cell, representing between 0.7% and 19.6% of the total hemoglobin with a mean value of 7.0%. The absolute content of HbF was indistinguishable in the well-hemoglobinized progeny of marrow erythroid colony-forming units, marrow or blood BFU-E, or of mixed colony-forming units. The term HbF program refers to this inherent capacity to produce fetal hemoglobin (HbF) in the erythroid cells derived from these progenitors in vitro. The HbF content of marrow erythroblasts as determined by the same radioligand immunoassay was similar to that found in the peripheral blood, suggesting that the switch off of γ-chain production occurs after the erythroid colony-forming unit stage of maturation. Increasing concentrations of a crude erythropoietin-containing preparation induced higher numbers of erythroid colonies, which were larger in size, but the HbF program was unaffected. In contrast to the hemoglobin accumulation in human progenitor-derived colonies, simian progenitor-derived colonies produced considerably more HbF, and the amount of HbF was strongly influenced by progenitor maturity. Assays of the HbF content of erythroblasts derived from culture of the peripheral blood BFU-E of patients with nondeletion hemoglobinopathies and their parents showed that the HbF program in the progenitors of such patients is highly variable. Some produce only a slight excess of HbF in progenitor-derived erythroblasts, whereas others have extraordinarily high HbF programs. The molecular basis of this variability is presently unknown.

UR - http://www.scopus.com/inward/record.url?scp=0021997550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021997550&partnerID=8YFLogxK

M3 - Article

C2 - 2580859

AN - SCOPUS:0021997550

VL - 75

SP - 1359

EP - 1368

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -